Fate Therapeutics (FATE) to Release Earnings on Thursday

Fate Therapeutics (NASDAQ:FATE) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. The business had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $0.85 million. Fate Therapeutics had a negative return on equity of 38.17% and a negative net margin of 253.30%. During the same period in the previous year, the firm posted ($0.58) earnings per share. On average, analysts expect Fate Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fate Therapeutics Trading Down 8.1 %

NASDAQ:FATE opened at $3.88 on Wednesday. The stock has a fifty day moving average price of $6.23 and a 200 day moving average price of $4.71. The firm has a market cap of $441.62 million, a PE ratio of -2.37 and a beta of 1.80. Fate Therapeutics has a 12-month low of $1.63 and a 12-month high of $8.83.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wedbush reissued a “neutral” rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Monday. Morgan Stanley boosted their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Tuesday, March 19th. BMO Capital Markets lifted their price target on shares of Fate Therapeutics from $6.00 to $7.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 27th. Finally, Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Fate Therapeutics has an average rating of “Hold” and an average target price of $6.90.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.